Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15900644 | 0.89 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL12802832 | 0.89 | CHRNB2 (0.36) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20863618 | 0.82 | TRPM8 (0.37) | ADH1CADH1ATRPM8HPGD | |
| SCHEMBL6042965 | 0.78 | ADH1C (0.37) | ADH1CADH1ATRPM8CES2CES1 | |
| SCHEMBL809692 | 0.76 | CES2 (0.35) | GRIN1GRIN2BCES2CES1PADI4 | |
| SCHEMBL814591 | 0.76 | CES2 (0.35) | GRIN1GRIN2BCES2CES1PADI4 | |
| SCHEMBL761935 | 0.75 | CES2 (0.38) | GRIN1GRIN2BCES2CES1PADI4 | |
| SCHEMBL27919866 | 0.73 | SLC6A1 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23749603 | 0.73 | HTT (0.47) | GRIN1GRIN2BCES2CES1PADI4 | |
| SCHEMBL9743609 | 0.73 | HTT (0.47) | GRIN1GRIN2BCES2CES1PADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449488-B2 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1511751-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | NEOGENESIS PHARMACEUTICALS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20060094706-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2006-05-04 | — | — | US | disclosed |
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | NEOGENESIS PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | RNGTT, PNP, ZC3HAV1 | ADH1C 1104/4885ADH1A 1681/4885CHRNB2 4882/4885 |
| US-20060094706-A1 | Pyrazolopyrimidines as protein kinase inhibitors | CDKN1A, EIF2AK2, DCK | ADH1C 2468/4885ADH1A 3294/4885CHRNB2 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.